TITLE

Global Report

PUB. DATE
June 2010
SOURCE
Pharmaceutical Representative;Jun2010, Vol. 40 Issue 6, p10
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers world news briefs related to pharmaceutical industry including the publication of a summary report by the European Medicines Agency (EMA) after completing the first phase of a project designed for the development of the European Union regulatory process and the investigation made by the French Competition Authority regarding the complaint from Teva Pharmaceuticals Industries Ltd. regarding the anti-competitive behavior of Sanofi-Aventis.
ACCESSION #
51363072

 

Related Articles

  • News bites.  // Pharmaceutical Technology Europe;Jul2011, Vol. 23 Issue 7, p8 

    The article offers pharmaceutical news briefs in Europe including the criticisms faced by the European Medicines Agency on transparency, the settlement of a sex-discrimination lawsuit by AstraZeneca, and the action on patient noncompliance which brings focus to the pharmaceutical industry.

  • News bites.  // Pharmaceutical Technology Europe;Nov2011, Vol. 23 Issue 11, p10 

    The article offers news briefs related to various pharmaceutical companies which include European Medicines Agency's call for a feedback on the use of biosimilar medicines and influenza vaccines, AstraZeneca PLC's investment in an intravenous drugs manufacturing company to be established in...

  • Life in life sciences: Is the boom in legal services set to last? Bernal, Natasha // Lawyer (Online Edition);12/15/2014, p1 

    The article reports that the European Medicines Agency (EMA) will publish clinical trial data alongside clinical trial reports from January 1, 2015, making information about clinical trials and data gathered by pharmaceutical companies available to the general public.

  • EU Agencies Update.  // Applied Clinical Trials;Dec2008, Vol. 17 Issue 12, p68 

    The article focuses on the responsibility for pharmaceuticals in Europe. It is divided between the governments of the 27 member states and the European Union's agencies. The principal EU institutions concerned are the European Commission in Brussels, Belgium and the European Medicines Agency...

  • Taking on the regulators: is it worth it? Wittner, Peter // Pharmaceutical Technology Europe;Aug2010, Vol. 22 Issue 8, p21 

    The article offers the author's insights on biosimilar regulatory frameworks with emphasis on regulated biosimilar market and unregulated market in Europe. He notes that the European Medicines Agency (EMA) has refined its biosimilar guidelines to cover specific classes of biosimilar products,...

  • News bites.  // Pharmaceutical Technology Europe;Nov2010, Vol. 22 Issue 11, p8 

    The article offers news briefs in the pharmaceutical industry in Europe, including the hostile tender offer by Sanofi-Aventis UK of 69 dollars per share for all outstanding shares of Genzyme Corp., the need for pharmaceutical companies to ensure patients have access to objective, unbiased...

  • The Sum of All His Parts: CAREER REFLECTIONS OF EUROPE'S CHIEF DRUG REGULATOR.  // Pharmaceutical Executive;Dec2010, Vol. 30 Issue 12, p36 

    An interview with European Medicines Agency director Thomas Lonngren is presented. He discusses the transition he had achieved that has helped the country's position as the world's largest market for medicines. He emphasizes the main aim of the Agency which is to stimulate innovation and promote...

  • EU Agencies Update.  // Applied Clinical Trials;Dec2010, Vol. 19 Issue 12, p62 

    The article provides update on the agencies handling the regulatory and policy responsibility for pharmaceuticals in the European Union (EU). The European Commission in Brussels maintains and updates the pharmaceutical legislation of EU and ensures its proper implementation. The European...

  • Seeking Greater Coordination, EMA Forms Another Committee. Sheridan, Cormac // BioWorld International;5/2/2012, Vol. 17 Issue 18, p2 

    This article reports on the decision of the European Medicines Agency (EMA) to establish a new scientific coordination board in May 2012. The decision is a response to an increasingly complex system of committees, which threatens to affect the pharmaceutical regulation in the region. The new...

  • Other News To Note.  // BioWorld Today;8/27/2012, Vol. 23 Issue 166, p7 

    This section offers news briefs on the pharmaceutical industry, including the agreement of the European Medicines Agency to precautionary measures dealing with manufacturing deficiencies that could impact the sterility of the DepoCyte cancer drug from Pacira Pharmaceuticals Inc. and the poster...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics